Applications of SAA1 protein in inducing the maturation and activation of immature dendritic cells and the application of Tripterygium wilfordii active ingredients in the preparation of drugs inhibiting SAA1-induced dendritic cell activation.

By inducing the maturation of immature dendritic cells with SAA1 protein and inhibiting their abnormal activation with triptolide, the problems of incomplete maturation and individual heterogeneity of dendritic cells in existing technologies are solved, achieving stable maturation and control of inflammatory factors across individuals, which is applicable to a variety of inflammation-related diseases.

CN123107927APending Publication Date: 2026-11-17BEIJING HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611481457.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-22
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively induce the maturation of immature dendritic cells and address the abnormal activation in SAA1-related inflammatory states. Traditional activators exhibit individual heterogeneity and functional defects, and there is a lack of specific intervention substances targeting SAA1-induced activators.

Method used

SAA1 protein was introduced into immature dendritic cells at concentrations ranging from 0.1 ng/mL to 10 μg/mL for 6–8 hours to promote dendritic cell maturation. Simultaneously, triptolide and triptolide were used to inhibit SAA1-induced dendritic cell activation.

Benefits of technology

SAA1 protein significantly promotes dendritic cell maturation, enhances surface molecule expression and pro-inflammatory cytokine secretion, while triptolide and triptolide effectively inhibit abnormal dendritic cell activation, reduce inflammatory cytokine expression and secretion, providing a cross-individual stable and broadly applicable intervention strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107927A_ABST
    Figure CN123107927A_ABST
Patent Text Reader

Abstract

This application provides the use of SAA1 protein in inducing the maturation and activation of immature dendritic cells and the use of Tripterygium wilfordii active ingredients in the preparation of drugs that inhibit SAA1-induced dendritic cell activation, belonging to the field of biomedical technology. According to one embodiment of this application, the use of SAA1 protein in inducing the maturation and activation of immature dendritic cells includes: contacting the SAA1 protein with immature dendritic cells; the induction concentration of the SAA1 protein is 0.1 ng / mL to 10 μg / mL, and the induction time is 6-8 hours. According to another embodiment of this application, the use of Tripterygium wilfordii active ingredients in the preparation of drugs that inhibit SAA1-induced dendritic cell activation is provided; the Tripterygium wilfordii active ingredients are triptolide and / or triptolide A.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of biomedicine, and in particular to the application of SAA1 protein in inducing the maturation and activation of immature dendritic cells, and the application of Tripterygium wilfordii active ingredients in the preparation of drugs that inhibit SAA1-induced dendritic cell activation. Background Technology

[0002] Dendritic cells (DCs), as the most potent professional antigen-presenting cells in the immune system, play a central role in the initiation and regulation of the body's adaptive immune response. Their unique antigen processing and presentation mechanisms and maturation transformation characteristics provide an important entry point for studying the regulatory mechanisms of immune responses. Although DCs exist in various tissues in vivo, their concentrations are too low to meet the needs of scientific research and clinical treatment. Therefore, various methods have been explored for the in vitro culture and expansion of DCs. While current mainstream stimulation protocols using TNF-α, LPS, and CD4+ OL can drive partial maturation of DCs, their functional characteristics still fall significantly short of the highly mature state required for clinical treatment. Therefore, a new method for inducing the maturation and activation of immature dendritic cells is needed.

[0003] Meanwhile, in SAA1-related diseases, persistently elevated SAA1 levels may be involved in maintaining the inflammatory microenvironment, altering immune cell status, and amplifying inflammatory signals. Dendritic cells, as key antigen-presenting cells connecting innate and adaptive immunity, can experience abnormal activation that exacerbates inflammatory cytokine release, enhances antigen presentation, and persists the immune response. Therefore, in SAA1-related inflammatory states, identifying interventions that can reduce abnormal dendritic cell activation is crucial for blocking immune amplification processes within the inflammatory microenvironment. Summary of the Invention

[0004] In view of the above, in order to at least partially solve at least one of the aforementioned technical problems, this application provides the application of SAA1 protein in inducing the maturation and activation of immature dendritic cells and the application of Tripterygium wilfordii active ingredient in the preparation of a drug that inhibits SAA1-induced dendritic cell activation.

[0005] According to one embodiment of this application, an application of SAA1 protein for inducing the maturation and activation of immature dendritic cells is provided, comprising: contacting immature dendritic cells with SAA1 protein; the induction concentration of SAA1 protein is 0.1 ng / mL to 10 μg / mL, and the induction time is 6 to 8 hours.

[0006] According to the implementation scheme of this application, SAA1 can significantly promote the expression of surface molecules on dendritic cells, covering a more comprehensive spectrum of surface markers, such as CD40, CD83, CD80, CD86, and MHCII, compared to the traditional activator LPS. This enhances the antigen-presenting ability of surface immune molecules, activates T cells, and promotes dendritic cell maturation. Furthermore, RT-qPCR analysis revealed that SAA1 exhibits a significant advantage in inducing inflammatory gene expression: its IL-12 mRNA expression level increased 900-fold from baseline, reaching 20-fold that of LPS, and the upregulation of IL-6, TNF-α, and IL-1β all exceeded that of LPS. Cell supernatant analysis using CBA showed that SAA1 can promote the secretion of more pro-inflammatory factors by dendritic cells, including IL-12, TNF-α, IL-6, and IL-1β. Cell phagocytosis experiments showed that SAA1 can reduce the phagocytic capacity of dendritic cells, and the phagocytic capacity is lower than that of the positive control LPS, consistent with the biological principle that mature DCs exhibit enhanced antigen presentation and weakened phagocytic function. Notably, the induction effect of SAA1 protein exhibits cross-individual stability, maintaining a highly consistent mature phenotype in cells from different donor sources, overcoming the limitations of traditional activators affected by individual heterogeneity. In terms of time-dependent effects, SAA1 can trigger the complete maturation program of dendritic cells within a very short induction time (8 hours compared to 48 hours with conventional LPS), significantly compressing its action window and demonstrating superior efficacy compared to traditional methods.

[0007] According to another embodiment of this application, the use of Tripterygium wilfordii active ingredient in the preparation of a drug for inhibiting SAA1-induced dendritic cell activation is provided; the Tripterygium wilfordii active ingredient is triptolide and / or triptolide A.

[0008] According to the implementation scheme of this application, triptolide and triptolide can inhibit SAA1-induced activation of dendritic cells derived from human monocytes, and can reduce the expression of dendritic cell maturation or antigen presentation-related molecules such as HLA-DR, CD86, and CD83 induced by recombinant SAA1, indicating that they can inhibit the transformation of dendritic cells from an immature state to an immune-activated state. At the same time, they can reduce the secretion of inflammatory factors such as IL-6, TNF-α, and IL-1β induced by recombinant SAA1, and can reduce the expression of IL6, TNF, and IL1B mRNA, indicating that they can inhibit SAA1-induced dendritic cell inflammatory response at the transcriptional level, providing a new intervention strategy for abnormal dendritic cell activation under high-level SAA1-related inflammatory conditions. This application compares the effects of triptolide, triptolide, and wilforine on SAA1-induced dendritic cell activation. The results show that triptolide and triptolide have superior inhibitory effects, indicating that different active components of Tripterygium wilfordii do not all have equivalent effects, thus providing experimental evidence for the selection of optimal active components. This application is not limited to a specific single disease but targets SAA1-related inflammatory diseases, diseases related to abnormal dendritic cell activation, autoimmune diseases, chronic inflammatory diseases, inflammation-related fibrotic diseases, or tissue damage-related inflammatory diseases, thus having a broad scope of application. Furthermore, this application provides a candidate substance screening system based on SAA1-induced dendritic cell activation, which can be used to discover more candidate drugs or intervention strategies that can inhibit SAA1-related abnormal dendritic cell activation. Attached Figure Description

[0009] The above and other objects, features and advantages of this application will become clearer from the following description of embodiments with reference to the accompanying drawings, in which:

[0010] Figure 1 This is a schematic diagram of the experimental process of SAA1 inducing maturation and activation of mouse bone marrow-derived dendritic cells in Example 1 of this application;

[0011] Figure 2 This is a flow cytometry result of Example 1 of this application, showing the results of SAA1-stimulated BMDC maturation and activation immunomolecular phenotype detection, including CD80, CD86, MHCII, CD40, and CD83.

[0012] Figure 3 The image shows the results of RT-qPCR detection of SAA1-stimulated BMDCs-related inflammatory factor mRNA expression in Example 1 of this application, including IL-1β, IL-6, TNF-α, and IL-12.

[0013] Figure 4This is a flow cytometry result of Example 2 of this application, showing the immunogenicity of SAA1-stimulated MoDCs maturation and activation, including CD86, CD80, and HLA-DR.

[0014] Figure 5 This is a flow cytometry result of Example 2 of this application, showing the phagocytic function of SAA1-stimulated MoDCs, including CD80, CD86, and HLA-DR.

[0015] Figure 6 This is a diagram showing the results of RT-qPCR detection of SAA1-stimulated MoDCs-related inflammatory factor mRNA expression in Example 2 of this application, including IL-1β, IL-6, and TNF-α.

[0016] Figure 7 This is a flow cytometry result diagram of the multifactor flow cytometry detection of inflammatory factors secreted in the supernatant of SAA1-stimulated MoDCs cells using a flow microsphere array (CBA) according to Example 2 of this application, including IL-6, TNF-α, IL-1β, IL-12, IL-10, and IL-4.

[0017] Figure 8 This is a graph showing the results of Western blot analysis of the expression level of the inflammatory factor TNF-α in SAA1-stimulated MoDCs cells in Example 2 of this application.

[0018] Figure 9 Figure 4 shows the effect of Celastrol, Triptolide, and Wilforine on rSAA1-induced HLA-DR and CD86 expression in human monocyte-derived dendritic cells in Example 4 of this application.

[0019] Figure 10 Figure 4 shows the effect of celastrol, triptolide, and wilforine on rSAA1-induced CD83 expression in human monocyte-derived dendritic cells in Example 4 of this application.

[0020] Figure 11 This is a graph showing the effects of Celastrol, Triptolide, and Wilforine on rSAA1-induced secretion of inflammatory factors in human monocyte-derived dendritic cells, as described in Example 5 of this application.

[0021] Figure 12 The figure shows the effect of Celastrol, Triptolide, and Wilforine on the mRNA expression of IL6, TNF, and IL1B induced by rSAA1 in human monocyte-derived dendritic cells, according to Example 6 of this application.

[0022] Figure 13 The figure shows the effect of Celastrol, Triptolide, and Wilforine on the temporal gradient of rSAA1-induced transcription of inflammatory factors in mouse bone marrow-derived dendritic cells in Example 7 of this application. Detailed Implementation

[0023] The embodiments of this application will now be described with reference to the accompanying drawings. However, it should be understood that these descriptions are exemplary only and are not intended to limit the scope of this application. In the following detailed description, numerous specific details are set forth to provide a thorough understanding of the embodiments of this application for ease of explanation. However, it will be apparent that one or more embodiments may be implemented without these specific details. Furthermore, descriptions of well-known structures and technologies are omitted in the following description to avoid unnecessarily obscuring the concepts of this application.

[0024] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of this application. The term "comprising" as used herein indicates the presence of features, steps, or operations, but does not exclude the presence or addition of one or more other features.

[0025] When using expressions such as "at least one of A, B, and C," the expression should generally be interpreted in accordance with the meaning commonly understood by a person skilled in the art (e.g., "a system having at least one of A, B, and C" should include, but is not limited to, a system having A alone, a system having B alone, a system having C alone, a system having A and B, a system having A and C, a system having B and C, and / or a system having A, B, and C, etc.). When using expressions such as "at least one of A, B, or C," the expression should generally be interpreted in accordance with the meaning commonly understood by a person skilled in the art.

[0026] The term "treatment" refers to exposing a subject to (e.g., administering medication) a drug, composition, or similar substance based on this application after the subject has contracted a disease, thereby reducing the symptoms of the disease compared to when the subject has not been exposed. It does not imply that the symptoms of the disease must be completely suppressed. Contracting a disease means that the body has developed symptoms of a disease.

[0027] The term "prevention" refers to the reduction of symptoms after the onset of a disease by exposing (e.g., administering medication) a subject to a drug, composition, etc. based on this application before the onset of the disease, compared to the absence of exposure, and does not imply the necessity of completely suppressing the disease.

[0028] The term "operably linked" refers to the linkage of a first polynucleotide molecule (e.g., a promoter) to a second transcribed polynucleotide molecule (e.g., a target gene), wherein the polynucleotide molecules are arranged such that the first polynucleotide molecule influences the function of the second polynucleotide molecule. Preferably, the two polynucleotide molecules are portions of a single, consecutive polynucleotide molecule, and more preferably, they are adjacent. For example, if a promoter regulates or mediates the transcription of a target gene within the cell, then the promoter is operably linked to the target gene.

[0029] In realizing the concept of this application, it was discovered that the biological characteristics of dendritic cells (DCs) exhibit significant developmental stage differences: immature dendritic cells (iDCs) colonizing peripheral non-lymphatic tissues possess active antigen uptake and chemotactic migration characteristics, but have weak T cell activation capabilities; upon recognizing pathogen-related molecular patterns through pattern recognition receptors, iDCs initiate a maturation process, gradually losing their phagocytic function and upregulating the expression of major histocompatibility complex (MHC) molecules and co-stimulatory molecules, transforming into mature dendritic cells (mDCs). These mDCs then migrate to secondary lymphoid organs via the lymphatic circulation. Mature DCs have a strong ability to induce naive T cell activation and simultaneously stimulate naive T cells to specifically activate CD8+ T cells or CD4+ T cells, thereby activating the immune response—a function 100–1000 times greater than that of macrophages in innate immunity and B cells in adaptive immunity. Furthermore, DCs can also activate humoral immune responses, stimulating B cell activation and proliferation through various mechanisms to exert immune effects.

[0030] Currently, conventional methods for inducing immature dendritic cells (DCs) in vitro mainly fall into two categories: For humans, the most common method is to induce DC production from human peripheral blood mononuclear cells (PBMCs). CD14+ monocytes are isolated from PBMCs using immunomagnetic bead sorting technology and then cultured for 5 days with recombinant human GM-CSF (rhGM-CSF) and recombinant human IL-4 (rhIL-4) to differentiate them into monocyte-derived dendritic cells (MoDCs). For mice, recombinant mouse granulocyte-macrophage colony-stimulating factor (rmGM-CSF) combined with recombinant mouse interleukin-4 (rmIL-4) is typically used to induce bone marrow progenitor cells to differentiate into bone marrow-derived dendritic cells (BMDCs).

[0031] In vitro maturation induction strategies for dendritic cells (DCs) still face key bottlenecks in the field of tumor immunotherapy. Although current mainstream TNF-α, LPS, and CD4 OL stimulation regimens can drive partial maturation of DCs, their functional characteristics still fall significantly short of the highly mature state required for clinical treatment.

[0032] TNF-α, a core molecule in anti-tumor immunity, is typically used as a stimulator to promote dendritic cell (DC) maturation, but its ability to induce DC maturation is the weakest among the three stimulators. TNF-α and GM-CSF can synergistically promote DC differentiation and maturation, and activated DCs can further activate autologous T cells to achieve anti-tumor effects. TNF-α stimulation of DC maturation is ineffective. The main problem lies in the functional defects of TNF-α-activated DCs, which are almost unable to secrete IL-12 after maturation. This functional defect directly leads to insufficient antigen presentation efficiency, making it difficult to elicit an effective Th1 immune response. Notably, unidimensional activation of the NF-κB pathway by TNF-α may trigger pro-apoptotic signals, resulting in decreased DC survival and further diminishing its clinical application potential.

[0033] Lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria, activates the maturation process of dendritic cells (DCs) by binding to Toll-like receptor 4 (TLR4) on the surface of DCs. LPS activates both MyD88-dependent and TRIF-dependent signaling pathways through the TLR4 / MD-2 complex. LPS can also promote IL-1β secretion by activating the NLRP3 inflammasome, further enhancing the immune activation function of DCs and theoretically inducing full DC maturation. However, LPS-induced dendritic cell activation has limitations: 1. Concentration-dependent effect: Low concentrations of LPS may induce DCs to remain in a semi-mature state, characterized by insufficient expression of co-stimulatory molecules and limited secretion of pro-inflammatory factors, leading to immune tolerance rather than activation. 2. Immune tolerance: Over-activation of the NLRP3 inflammasome induced by LPS may disrupt the IL-1β / IL-12 secretion balance, increasing the risk of immune tolerance. 3. Physiological maturation deviation: DCs stimulated by LPS in vitro differ from physiologically mature DCs in terms of migration ability and T cell activation efficiency, potentially affecting the clinical translation of therapeutic vaccines.

[0034] CD40 ligand (CD40L) activates both classical and non-classical NF-κB signaling pathways by binding to the CD40 receptor on the surface of dendritic cells (DCs), driving DC maturation. CD40-CD40L interaction promotes the recruitment of TRAF2 / 5 / 6 aptamers, activates the IKK complex and induces NF-κB nuclear translocation, and upregulates the expression of maturation markers such as CD83 and CD86. Simultaneously, CD40L enhances DC viability through the PI3K / Akt pathway and promotes IL-12p70 secretion through STAT3 phosphorylation, thereby enhancing the Th1 immune response. However, over-activated CD40 signaling may induce abnormal secretion of IL-6 and IL-10, promoting the differentiation of immunosuppressive Treg cells. Furthermore, this family of proteins is characterized by its ability to function only after trimer formation. Therefore, stimulating DCs with recombinant CD40L trimer protein yields the best results. Stimulating DCs with CD40L monomers often results in low maturation rates. It is worth noting that leukemia-derived dendritic cells (DCs) retain chromosomal abnormalities from the original tumor cells after CD40L stimulation, which may lead to treatment failure through immune escape mechanisms.

[0035] The SAA family has four members: SAA1 and SAA2 are acute-phase reactants, SAA4 is a constitutively expressed protein, and SAA3 is a pseudogene in humans but is expressed in mouse adipocytes, especially in obese mice. These genes are located in adjacent regions of the same chromosome, and SAA1 and SAA2 are reverse-transcribed from the same promoter, exhibiting high homology (only 6 amino acids out of 104 differ). As core acute-phase reactants on par with C-reactive protein (CRP), plasma concentrations of SAA1 and SAA2 can increase approximately 1000-fold under acute inflammatory stimulation. SAA exhibits rapid synthesis characteristics in response to pathophysiological challenges such as trauma, pathogen invasion, malignant tumor progression, surgical intervention, and severe stress. Its low basal expression level and high inducible expression characteristics perfectly match the biological characteristics of endogenous danger signaling molecules. Notably, SAA not only accumulates significantly in infectious inflammatory foci but also shows persistently high expression in aseptic inflammatory pathologies such as atherosclerosis and rheumatoid arthritis.

[0036] Studies have shown that rhSAA stimulates IL-33 expression and regulates various functions of immune cells. SAA1 can bias giant cells towards the M2 phenotype, including enhanced ability to clear apoptotic neutrophils (exocytosis) and induction of cell surface protein expression. High levels of SAA protein have been found in the joints of patients with rheumatoid arthritis, blood vessels with atherosclerotic lesions, and many types of solid tumors. Given the potent effects of rhSAA on inflammatory cells, SAA may be considered a mediator of "danger signals" influencing the inflammatory process. Given existing evidence, SAA, through its chemotactic activity and cytokine network regulatory function, may have similarly profound effects on dendritic cells, the most potent antigen-presenting cells in the immune system.

[0037] Based on this, one embodiment of this application provides an application of SAA1 protein for inducing the maturation and activation of immature dendritic cells, comprising: contacting immature dendritic cells with SAA1 protein; the induction concentration of SAA1 protein is 0.1 ng / mL to 10 μg / mL, and the induction time is 6 to 8 hours.

[0038] According to the embodiments of this application, the induction concentration of SAA1 protein can be 0.1 ng / mL, 1 ng / mL, 10 ng / mL, 100 ng / mL, 1 μg / mL, 3 μg / mL, 5 μg / mL, 8 μg / mL, or 10 μg / mL, but is not limited to the listed values. Other unlisted values ​​within this range are also applicable; or a range consisting of any two values, such as 0.1 ng / mL to 1 μg / mL.

[0039] In one or more specific embodiments of this application, the inducible concentration of SAA1 protein is from 0.1 μg / mL to 5 μg / mL.

[0040] In a more specific embodiment of this application, the induction concentration of SAA1 protein is 0.5 μg / mL.

[0041] According to the implementation scheme of this application, SAA1 can significantly promote the expression of surface molecules on dendritic cells, covering a more comprehensive spectrum of surface markers, such as CD40, CD83, CD80, CD86, and MHCII, compared to the traditional activator LPS. This enhances the antigen-presenting ability of surface immune molecules, the ability to activate T cells, and promotes dendritic cell maturation. Furthermore, RT-qPCR analysis revealed that SAA1 exhibits a significant advantage in inducing inflammatory gene expression: its IL-12 mRNA expression level increased 900-fold from baseline, reaching 20-fold that of LPS, and the upregulation of IL-6, TNF-α, and IL-1β all exceeded that of LPS. Cell supernatant analysis using CBA showed that SAA1 can promote the secretion of more pro-inflammatory factors by dendritic cells, including IL-12, TNF-α, IL-6, and IL-1β. Cell phagocytosis experiments showed that SAA1 can reduce the phagocytic capacity of dendritic cells, and the phagocytic capacity is lower than that of the positive control LPS, consistent with the biological principle that mature DCs exhibit enhanced antigen-presenting function and weakened phagocytic function. Notably, the induction effect of SAA1 protein exhibits cross-individual stability, maintaining a highly consistent mature phenotype in cells from different donor sources, overcoming the limitations of traditional activators affected by individual heterogeneity. In terms of time-dependent effects, SAA1 can trigger the complete maturation program of dendritic cells within a very short induction time (8 hours compared to 48 hours with conventional LPS), significantly compressing its action window and demonstrating superior efficacy compared to traditional methods.

[0042] According to the embodiments of this application, the activator LPS induces DCs to a semi-mature state at low concentrations, leading to immune tolerance rather than activation. The preferred SAA1 concentration range ensures the acquisition of mature DCs with complete antigen presentation function and pro-inflammatory factor secretion capacity. At the preferred concentration of 0.5 μg / mL, SAA1 can simultaneously induce high levels of expression of CD40, CD83, CD80, CD86, and MHCII, while conventional LPS at this concentration can only significantly upregulate CD40 and CD83 within 6 hours. Therefore, the scheme of this application achieves superior T cell activation capacity compared to conventional activators.

[0043] According to the implementation scheme of this application, the immature dendritic cells are immature dendritic cells derived from human mononuclear cells. The immature dendritic cells derived from human mononuclear cells are obtained and matured and activated through the following steps S11 to S13:

[0044] Step S11: Mononuclear cells are isolated from the peripheral blood of the subject and CD14-positive mononuclear cells are obtained by sorting with CD14 magnetic beads;

[0045] Step S12: Inducing and culturing CD14-positive monocytes in a medium containing granulocyte-macrophage colony-stimulating factor and interleukin-4 to differentiate into immature dendritic cells;

[0046] Step S13: Contact the immature dendritic cells with SAA1 protein to activate and mature them, thus obtaining mature dendritic cells.

[0047] According to the embodiments of this application, in steps S11 to S13, the concentration of granulocyte-macrophage colony-stimulating factor is 80 ng / mL to 120 ng / mL, preferably 100 ng / mL.

[0048] According to the implementation scheme of this application, in steps S11 to S13, the concentration of granulocyte-macrophage (GM-CSF) colony-stimulating factor can be 80 ng / mL, 90 ng / mL, 100 ng / mL, 110 ng / mL, or 120 ng / mL, but is not limited to the listed values. Other unlisted values ​​within this range are also applicable; or within a range consisting of any two values, such as 80 ng / mL to 100 ng / mL.

[0049] According to the embodiments of this application, in steps S11 to S13, the concentration of interleukin-4 (IL-4) is 15 ng / mL to 25 ng / mL, preferably 20 ng / mL.

[0050] According to the implementation scheme of this application, in steps S11 to S13, the concentration of interleukin-4 (IL-4) can be 15 ng / mL, 18 ng / mL, 20 ng / mL, 23 ng / mL, or 25 ng / mL, but is not limited to the listed values. Other unlisted values ​​within this range are also applicable; or within a range consisting of any two values, such as 20 ng / mL to 25 ng / mL.

[0051] According to the implementation scheme of this application, CD14-positive monocytes obtained by CD14 magnetic bead sorting ensure the uniformity and stability of immature DCs during subsequent GM-CSF and IL-4 induction. This eliminates competitive uptake or paracrine interference from lymphocytes, NK cells, etc., of the SAA1 stimulation signal, allowing subsequent experimental results and clinical applications of SAA1-induced maturation to better reflect the true response of the DCs themselves, avoiding immune background noise from impurity cells. Under appropriate concentrations of GM-CSF and IL-4, the action window and dose-response relationship of SAA1 as a potent maturation inducer are ensured not to be distorted due to differences in cell origin. Consequently, monocytes can stably differentiate into a typical immature DC phenotype with high antigen uptake capacity and low co-stimulatory molecule expression within 5-6 days, ensuring the standardization of SAA1's substrate.

[0052] According to the implementation scheme of this application, the immature dendritic cells are immature dendritic cells derived from mouse bone marrow. The immature dendritic cells derived from mouse bone marrow are obtained and matured and activated through the following steps S21 to S23:

[0053] Step S21: Isolate bone marrow cells from mouse bone marrow, remove neutrophils by negative magnetic bead sorting, and obtain dendritic cell precursors;

[0054] Step S22: Induce and culture dendritic cell precursors in a medium containing granulocyte-macrophage colony-stimulating factor and interleukin-4 to differentiate into immature dendritic cells;

[0055] Step S23: Contact the immature dendritic cells with SAA1 protein to activate and mature them, thus obtaining mature dendritic cells.

[0056] According to the embodiments of this application, in steps S21 to S23, the concentration of granulocyte-macrophage colony-stimulating factor is 15 ng / mL to 25 ng / mL, preferably 20 ng / mL;

[0057] According to the implementation scheme of this application, in steps S21 to S23, the concentration of granulocyte-macrophage (GM-CSF) colony-stimulating factor can be 15 ng / mL, 18 ng / mL, 20 ng / mL, 23 ng / mL, or 25 ng / mL, but is not limited to the listed values. Other unlisted values ​​within this range are also applicable; or within a range consisting of any two values, such as 15 ng / mL to 20 ng / mL.

[0058] According to the embodiments of this application, in steps S21 to S23, the concentration of interleukin-4 is 5 ng / mL to 15 ng / mL, preferably 10 ng / mL.

[0059] According to the implementation scheme of this application, in steps S21 to S23, the concentration of interleukin-4 (IL-4) can be 5 ng / mL, 8 ng / mL, 10 ng / mL, 13 ng / mL, or 15 ng / mL, but is not limited to the listed values. Other unlisted values ​​within this range are also applicable; or within a range consisting of any two values, such as 10 ng / mL to 15 ng / mL.

[0060] According to the implementation scheme of this application, the unsorted scheme has two major hidden dangers: first, reactive oxygen species and elastase secreted by neutrophils can inhibit the expression of dendritic cell maturation markers; second, DNA fragments (NETs) and mitochondrial components released by apoptotic neutrophils can interfere with the antigen presentation function of dendritic cells. By removing neutrophils through negative magnetic bead sorting, the aforementioned interfering signals are cut off at the source. This ensures that all subsequent stimulation effects of SAA1 on dendritic cell precursors and subsequently differentiated immature DCs (such as upregulation of CD80 / CD86 / MHCII, decreased phagocytic function, and high expression of IL-12) are directly attributed to the direct effect of SAA1 on DCs, rather than non-specific false-positive activation induced by impurity cells.

[0061] On the other hand, specifically, the removal of neutrophils significantly reduces their interference with dendritic cell (DC) maturation: firstly, reactive oxygen species and elastase secreted by neutrophils may inhibit the expression of dendritic cell maturation markers; secondly, DNA fragments (NETs) and mitochondrial components released by apoptotic neutrophils can interfere with the antigen-presenting function of dendritic cells by activating inflammatory signaling pathways. Therefore, neutrophil removal can optimize the stability and functionality of the induction system.

[0062] Furthermore, in realizing the concept of this application, it was found that existing anti-inflammatory or immunomodulatory drugs mainly focus on broadly inhibiting inflammatory responses, and there is a lack of substances that specifically intervene in the abnormal activation process of dendritic cells in the context of high SAA1 levels. In particular, whether different natural products or plant-derived active ingredients can inhibit SAA1-related dendritic cell activation responses, and whether there are differences in inhibitory effects among different active ingredients, still lack experimental evidence. Therefore, screening for candidate substances that can reduce abnormal activation of SAA1-related dendritic cells and clarifying their roles at the levels of dendritic cell maturation markers, inflammatory factor secretion, and inflammatory gene transcription has significant drug development value.

[0063] Tripterygium wilfordii and its derived active ingredients possess immunomodulatory activities, among which celastrol, triptolide, and wilforine are representative active ingredients. However, the effects of different active ingredients vary depending on the specific immune cells and inflammatory stimuli. Current technology has not clarified the differences in the effects of celastrol, triptolide, and wilforine on SAA1-induced dendritic cell maturation and activation, nor has it disclosed that celastrol and triptolide can inhibit SAA1-induced activation of human monocyte-derived dendritic cells, inflammatory cytokine secretion, and inflammatory gene transcription. Therefore, confirming the inhibitory effect of preferred active ingredients of Tripterygium wilfordii on SAA1-induced abnormal dendritic cell activation is of great significance for establishing drug intervention strategies for SAA1-related inflammatory diseases.

[0064] According to another embodiment of this application, the use of Tripterygium wilfordii active ingredient in the preparation of a drug for inhibiting SAA1-induced dendritic cell activation is provided; the Tripterygium wilfordii active ingredient is triptolide and / or triptolide A.

[0065] Specifically, dendritic cell activation includes increased expression of dendritic cell maturation markers, increased expression of antigen-presenting related molecules, increased expression of co-stimulatory molecules, increased expression of inflammatory factors, or increased secretion of inflammatory factors; maturation markers, antigen-presenting related molecules, or co-stimulatory molecules include one or more of HLA-DR, CD86, CD83, CD80, MHCII, and CD40; inflammatory factors include one or more of IL-6, TNF-α, IL-1β, and IL-12.

[0066] According to the implementation scheme of this application, triptolide and triptolide can inhibit SAA1-induced activation of dendritic cells derived from human monocytes, and can reduce the expression of dendritic cell maturation or antigen presentation-related molecules such as HLA-DR, CD86, and CD83 induced by recombinant SAA1, indicating that they can inhibit the transformation of dendritic cells from an immature state to an immune-activated state. At the same time, they can reduce the secretion of inflammatory factors such as IL-6, TNF-α, and IL-1β induced by recombinant SAA1, and can reduce the expression of IL6, TNF, and IL1B mRNA, indicating that they can inhibit SAA1-induced dendritic cell inflammatory response at the transcriptional level, providing a new intervention strategy for abnormal dendritic cell activation under high-level SAA1-related inflammatory conditions. This application compares the effects of triptolide, triptolide, and wilforine on SAA1-induced dendritic cell activation. The results show that triptolide and triptolide have superior inhibitory effects, indicating that different active components of Tripterygium wilfordii do not all have equivalent effects, thus providing experimental evidence for the selection of optimal active components. This application is not limited to a specific single disease but targets SAA1-related inflammatory diseases, diseases related to abnormal dendritic cell activation, autoimmune diseases, chronic inflammatory diseases, inflammation-related fibrotic diseases, or tissue damage-related inflammatory diseases, thus having a broad scope of application. Furthermore, this application provides a candidate substance screening system based on SAA1-induced dendritic cell activation, which can be used to discover more candidate drugs or intervention strategies that can inhibit SAA1-related abnormal dendritic cell activation.

[0067] According to the embodiments of this application, the active ingredient of Tripterygium wilfordii includes its pharmaceutically acceptable salt, derivative, analog, prodrug, crystal form, hydrate, solvate or pharmaceutical composition.

[0068] According to the embodiments of this application, the active ingredients of Tripterygium wilfordii do not include triptolide, or triptolide (Wilforine) is used as a comparative agent to evaluate the differences in the inhibitory effects of different active ingredients of Tripterygium wilfordii on SAA1-induced dendritic cell activation.

[0069] According to the implementation scheme of this application, the dendritic cells may also be peripheral blood-derived dendritic cells, tissue-derived dendritic cells, or a combination thereof.

[0070] According to the implementation scheme of this application, SAA1 is recombinant human SAA1 or recombinant mouse SAA1.

[0071] According to the implementation scheme of this application, SAA1-related diseases include: SAA1-elevation-related inflammatory diseases, SAA1-involved immune inflammatory diseases, dendritic cell abnormal activation-related diseases, autoimmune diseases, chronic inflammatory diseases, inflammation-related fibrotic diseases, tissue damage-related inflammatory diseases, post-infectious inflammatory responses, or aseptic inflammatory responses.

[0072] According to the implementation scheme of this application, the diseases include joint inflammation-related diseases, lung inflammation-related diseases, pulmonary fibrosis-related diseases, intestinal inflammation-related diseases, liver inflammation-related diseases, vascular inflammation-related diseases, post-infectious inflammatory syndromes, or autoimmune-related inflammatory diseases.

[0073] The technical solution of this application will be further explained below based on specific embodiments. Unless otherwise stated, all reagents used are commercially available reagents, and all experimental and testing methods used are conventional methods.

[0074] Example 1: Induction of maturation activation of mouse bone marrow-derived dendritic cells (BMDCs) by SAA1

[0075] Figure 1 This is a schematic diagram of the experimental process of SAA1 inducing maturation and activation of mouse bone marrow-derived dendritic cells in Example 1 of this application.

[0076] I. Inducing mouse bone marrow cells to become immature dendritic cells:

[0077] (1) Preparation of primary bone marrow single-cell suspension: All surgical instruments were sterilized by autoclaving, and the experiment was conducted in a Class II biosafety cabinet. Eight- to ten-week-old male C57BL / 6 mice were euthanized using CO2. The tibia, fibula, and femur were removed with surgical scissors and placed in a 10 cm culture dish containing 70% ethanol. The ends of the tibia and femur were trimmed using a scalpel. The bone marrow contents were flushed from one end of the bone into a centrifuge tube containing 12 mL of PBS using a syringe with a 23G needle containing 3 mL of PBS. This was repeated three times for each end of the bone. After centrifuging the cell suspension at 300×g for 10 min, the supernatant was discarded, and 10 mL of erythrocyte lysis buffer was added for lysis at room temperature for 5 min. After termination, the cells were centrifuged again to remove the lysis products. Finally, the cells were resuspended in PBS, filtered through a 200-mesh filter, and the cell density was adjusted to 1×10⁻⁶. 7 / mL for later use. To be used for subsequent magnetic bead sorting.

[0078] (2) Optimization of dendritic cell precursor purification and induction protocol based on negative magnetic bead sorting: Non-neutrophil targets were first indirectly labeled using Miltenyi's (catalog number 130-097-658) negative selection magnetic bead sorting method. After preparing single-cell suspensions of samples, biotinylate antibody cocktail (labeled with non-neutrophil surface antigen) and anti-biotin microbeads were added sequentially, followed by low-temperature incubation and washing. Subsequently, the cell suspension was loaded onto a suitable MACS LS column, where non-target cells were retained under the action of a magnetic field, and unlabeled neutrophils were directly collected as flow-through fluid.

[0079] The entire process requires low-temperature operation (2-8℃), using pre-cooled buffer (containing EDTA / BSA). Unlabeled neutrophils are collected via flow-through, and the washing is repeated three times. The sorting column is removed from the sorter and placed on a 15mL centrifuge tube. 5mL of MASC buffer is added to elute the non-neutrophils retained on the sorting column into a 15mL collection tube, which contains the target cells for induction: dendritic cell precursors. These are then induced into immature dendritic cells. The improved dendritic cell induction protocol uses magnetic bead sorting to remove neutrophil precursors, followed by GM-CSF and IL-4 induction to differentiate into immature dendritic cells.

[0080] II. In vitro differentiation induction of immature BMDCs

[0081] The cell number was adjusted to 1x10 using RPMI-1640 medium containing 20 ng / mL GM-CSF and 10 ng / mL IL-4. 6 Cells / mL. 6-well plate, 3 mL per well (1 x 10⁻⁶ cells / mL). 6 Cells / mL were incubated in a CO2 incubator at 37°C, 5% CO2, and 95% humidity. The medium was changed on day 3 and day 5 of culture.

[0082] The medium replacement method is as follows: Aspirate all culture medium from the culture system. Add 1 mL of complete culture medium containing the inducing factor to the original well. Centrifuge the aspirated cell suspension at 1000 rpm for 3 minutes, discard the supernatant, and resuspend the cells in 2 mL of complete culture medium containing the same inducing factor. Add the resuspended cells to the original well. After 5-7 days, the cells will change from suspension cells to semi-adherent cells, and typical dendritic cell clusters can be observed under a microscope, indicating successful induction. On day 6 of culture, aspirate all culture medium from the culture system and place it in a 15 mL centrifuge tube. Add 1 mL of trypsin to the well plate for digestion for 1-2 minutes, then add complete culture medium without the inducing factor to neutralize. At this time, aspirate the entire contents of the well plate into a 15 mL centrifuge tube. Note: Cells from each mouse should be placed in the same centrifuge tube, while cells from different mice should be placed in different centrifuge tubes. Centrifuge at 1000 rpm for 3 minutes, discard the supernatant, and resuspend the cells in culture medium without GM-CSF and IL-4. Adjust the cell count to 1 x 103. 6 Cells / mL, 1 mL per well in a 12-well plate.

[0083] The LPS positive control group was treated with 1 μg / mL LPS (MCE, HY-D1056), the SAA1 group was treated with 0.5 μg / mL rmSAA1 (Serum Amyloid A-1 protein, Mouse, MCE, HY-P79122), and the blank control wells were treated with an equal volume of PBS. After stimulation for 6 hours, cells and supernatants were collected. The induction effect of BMDCs was identified by flow cytometry using a fluorescently labeled CD11c antibody.

[0084] III. Experimental Verification of Mature BMDCs

[0085] (1) DCs surface co-stimulatory activating factor assay - flow cytometry: Dendritic cells highly express CD11c, so APC / CY7-CD11c was used to identify the dendritic cell induction ratio, and Zombie staining was used to remove non-specific staining of dead cells. First, the cell suspension to be tested was collected, centrifuged at 300×g for 5 minutes to remove the supernatant, and the cells were resuspended in 100ul PBS. In order to reduce non-specific binding, Fc receptor (1μg / tube) was blocked in advance, and after incubation at room temperature for 10 minutes, Zombie Violet live / dead dye (1μg / tube) was added, and after incubation at room temperature for 10 minutes, the cells were washed; the cells were resuspended in 100ul PBS buffer containing 1% BSA, and APC / CY7-CD11c, PerCP CY5.5-CD80, MHCII-PE, CD40-APC, AF488-CD86, and PE-CY7-CD83 specific antibodies were added, and the cells were stained and incubated at 4℃ in the dark for 30 minutes. After staining, cells were washed once with pre-chilled PBS to remove unbound antibodies. Cells were then resuspended in 200 μL of buffer. Forward scatter (FSC) and side scatter (SSC) signals were collected using flow cytometry to set cell population gating. CD11c-positive and Zombie Violet-negative cells were used to identify viable dendritic cells. Flow cytometry gating was used to analyze the percentage of CD86, CD80, MHC II, CD40, and CD83-positive cells in this cell population, quantifying changes in maturation marker expression. Fluorescence compensation correction was performed using a single-positive microsphere control. Data analysis was performed using FlowJo software, and the results are as follows: Figure 2 As shown.

[0086] Figure 2 This is a flow cytometry result of Example 1 of this application, showing the results of SAA1-stimulated BMDC maturation and activation immunomolecular phenotype detection, including CD80, CD86, MHCII, CD40, and CD83.

[0087] according to Figure 2As can be seen, under 6-hour induction conditions, SAA1 exhibited unique activation characteristics in four independent groups of mouse bone marrow-derived dendritic cells (BMDCs): compared to the classic stimulant LPS, which only significantly upregulated the expression of CD40 and CD83, SAA1 could simultaneously induce high-level expression of CD40, CD83, CD80, CD86, and MHCII molecules, while the LPS-treated group did not induce CD80, CD86, and MHCII at this time. Further experiments showed that SAA1 achieved CD40 / CD83 activation effects comparable to LPS in a shorter induction time (6 hours vs. conventional LPS 48 hours), while achieving a higher proportion of mature cell populations at lower doses. These data indicate that SAA1's activation effect on BMDCs not only covers a more comprehensive spectrum of surface markers but also outperforms LPS in terms of time efficiency, dose dependence, and maturity indices.

[0088] (2) Detection of DCs inflammation-related genes - RT-qPCR: RNA was extracted from dendritic cells using TRIzol (Invitrogen) and PrimeScript was used. TM RT Master Mix (Takara Bio) was used to convert RNA to cDNA. Real-time quantitative PCR was performed using SYBRPremix Ex Taq™ II (Takara Bio). Relative RNA expression levels were normalized relative to GAPDH mRNA using the ΔΔCt calculation method. Results are shown below. Figure 3 As shown.

[0089] The primers used are as follows:

[0090] β-Actin

[0091] Forward: SEQ ID NO.1: 5'- GGCTGTATTCCCCTCCATCG -3';

[0092] Reverse: SEQ ID NO.2: 5'-CCAGTTGGTAACAATGCCATGT-3'.

[0093] IL-1β

[0094] Forward: SEQ ID NO.3: 5'- GCAACTGTTCCTGAACTCAACT- 3';

[0095] Reverse: SEQ ID NO.4: 5'- ATCTTTTGGGGTCCGTCAACT- 3'.

[0096] TNF-α

[0097] Forward: SEQ ID NO.5: 5'- CCCTCACACTCAGATCATCTTCT- 3';

[0098] Reverse: SEQ ID NO.6: 5'- GCTACGACGTGGGCTACAG - 3'.

[0099] IL-6

[0100] Forward: SEQ ID NO.7: 5'- TAGTCCTTCCTACCCCAATTTCC- 3';

[0101] Reverse: SEQ ID NO.8: 5'- TTGGTCCTTAGCCACTCCTTC - 3'.

[0102] Figure 3 This is a graph showing the results of RT-qPCR detection of SAA1-stimulated BMDCs-related inflammatory factor mRNA expression in Example 1 of this application, including IL-1β, IL-6, TNF-α, and IL-12.

[0103] according to Figure 3 It can be seen that SAA1 significantly outperforms the classic stimulant LPS in inducing inflammation-related genes in bone marrow-derived dendritic cells (BMDCs). Under 6-hour induction conditions, IL-12 mRNA expression in the SAA1-treated group increased nearly 1000-fold (902-fold) compared to the control group, while the LPS group only reached 45-fold. Other key inflammatory factors also showed significant differences: IL-6 (30-fold vs. 15-fold), TNF-α (6-fold vs. 3-fold), and IL-1β (180-fold vs. 130-fold). This hierarchical gene expression advantage is particularly prominent among Th1 polarization-related factors such as IL-12, with its induction intensity reaching 20-fold (902 / 45) of LPS. This result, combined with the upregulation data of co-stimulatory molecules (CD80 / CD86 / MHC II) detected by flow cytometry, functionally correlates with the findings, indicating that SAA1 drives the establishment of an immune-activated phenotype in BMDCs by enhancing the transcriptional efficiency of inflammatory genes in multiple dimensions. Under the same dosage and time conditions, SAA1 exhibits a more comprehensive and stronger induction property on inflammatory cytokine gene clusters, which provides a molecular-level explanation for its high efficiency in regulating antigen presentation and T cell activation.

[0104] Example 2: SAA1-mediated induction of maturation activation in immature dendritic cells (MoDCs) derived from human monocytes

[0105] I. Induction of human peripheral blood mononuclear cells (PBMCs) into immature dendritic cells

[0106] (1) Isolation of human peripheral blood mononuclear cells: Peripheral blood was collected from three healthy subjects using K2E (EDTA) tubes (BD Vacutainer). To isolate PBMCs, the peripheral blood was first serially diluted with phosphate-buffered saline (PBS). An appropriate amount of Ficoll-Hypaqu separation solution was poured into a 15 mL centrifuge tube, and the diluted peripheral blood was then spread evenly on the top layer of the separation solution, taking care not to disrupt the interface. Centrifugation was then performed at 800 G (maximum ramp rate, minimum deceleration rate) for 20 minutes at room temperature. After centrifugation, the white suspended cells in the middle layer were aspirated with a pipette, which were the PBMCs. The next step was to add 10 mL of PBS to wash away excess Ficoll, and centrifuge again at 300 G for 10 minutes, retaining the PBMCs at the bottom of the centrifuge tube. The cells were resuspended in MASC and placed at 4 °C for downstream magnetic bead sorting.

[0107] (2) Obtaining CD14 mononuclear cells by magnetic bead sorting: Cell counting was performed on the PBMCs isolated by Ficol: If the cell count was ≤10 7 Add 80uL MASC Buffer and 20uL LCD14 Microbeads (if cell count >10). 7 (To be continued, the reagent volume needs to be increased.) Incubate at 4°C in the dark for 15 min. Wash cells with 5 mL of MASC Buffer, centrifuge at 300 x g for 10 min, discard the supernatant, and resuspend the cells in 500 μL of MASC Buffer. Column sorting: Install the sorting column onto the sorter, rinse the column with 5 mL of MASC Buffer, and add 500 μL of single-cell suspension to the sorting column using a pipette. After passing the suspension through the column, wash the column with 5 mL of MASC Buffer, repeating the washing three times. Remove the sorting column from the sorter and place it on a 15 mL centrifuge tube. Add 5 mL of MASC Buffer to elute the monocytes retained on the sorting column into a 15 mL collection tube, which is the CD14+ monocyte. The method was validated by flow cytometry using a CD14 (BioLegend) antibody; the purity of CD14+ PBMCs was greater than 98%. The sorted CD14+ PBMCs were immediately subjected to flow cytometry staining analysis, or stored for downstream induction and differentiation.

[0108] (3) In vitro differentiation of immature MoDCs: 3 x 10⁻⁶ CD14+ mononuclear cells isolated 6Cells were cultured in 6-well plates with 3 mL of complete medium (RPM1 1640, 10% FBS, 1% antibiotics) supplemented with 100 ng / mL GM-CSF (Sigma) and 20 ng / mL IL-4 (nearshore protein). The medium was observed daily, and when it turned yellow, the cells were changed (approximately every 2 days). The medium change method was as follows: aspirate all the medium from the culture system, add 1 mL of complete medium containing inducing factors to the original wells, centrifuge the aspirated cell suspension at 1000 rpm for 3 min, discard the supernatant, resuspend the cells in 2 mL of complete medium containing inducing factors, and add it to the original wells. Induction was successful when the cells changed from suspension cells to semi-adherent cells in 5-6 days. The cells were then collected, centrifuged, the supernatant was discarded, and the medium was replaced with an equal volume of complete medium without GM-CSF, ready for subsequent activation and maturation induction procedures.

[0109] II. Induction of activation and maturation of immature human dendritic cells (MoDCs)

[0110] (1) To induce cell activation and maturation, LPS (1 mg / mL) and rhSAA1 (SAA1 protein, Human, MCE, HY-P70510, 0.5 μg / mL) were added, respectively. LPS was used as a positive control and SAA1 was used as the experimental protein. After 6 hours of induction, cells and culture supernatant were collected. To observe the efficiency of induction and maturation, four experiments were designed based on the characteristics of dendritic cells to verify the induction efficiency of SAA1: phagocytic capacity of DCs, expression of co-stimulatory activating factors on the surface of DCs, expression of inflammation-related genes in DCs, and secretion of inflammatory factors in DCs.

[0111] (2) DCs phagocytosis experiment - flow cytometry: Mature dendritic cells induced by SAA1 were collected and prepared into 1×10⁻⁶ cells. 6 Cell suspensions at a concentration of [number] cells / mL were divided into two portions. One portion served as a control and was incubated at 4°C in the dark. The other portion was incubated with FITC-dextran (1 mg / mL) at 37°C for 40 min. After staining, the cells were centrifuged and the supernatant was discarded. The cells were washed once with 1 mL of pre-cooled PBS, then stained with 100 μL of Zombie Violet dye at room temperature for 10 min. 200 μL of PBS was added, and the fluorescence intensity of the live and dead dyes and FITC was detected by flow cytometry. The uptake and phagocytic function of the cells at this point was analyzed. The results are as follows: Figure 4 As shown.

[0112] Figure 4 This is a flow cytometry result of Example 2 of this application, showing the immunogenicity of SAA1-stimulated MoDCs maturation and activation, including CD86, CD80, and HLA-DR.

[0113] according to Figure 4It can be seen that when the cells are at 4℃, they are inactive and have a very weak phagocytic ability, while the dendritic cells in the control group still maintain a high phagocytic activity because no activating stimulant was added. After the addition of LPS, the phagocytic ability decreased as expected, which confirms the functional conversion of mature DCs from phagocytic mode to immune activation mode. The addition of SAA1 can further reduce the phagocytic ability, even lower than the positive control, which is consistent with the biological law that mature DCs have enhanced antigen presentation function and weakened phagocytic function. This indicates that SAA1 induces dendritic cell activation more strongly than LPS.

[0114] (3) DCs surface co-stimulatory activating factor assay - flow cytometry: dendritic cells highly express CD11C, so APC / CY7-CD11c was used to identify the dendritic cell induction ratio, and Zombie staining was used to remove non-specific staining of dead cells.

[0115] First, collect the cell suspension to be tested, centrifuge at 300×g for 5 minutes to remove the supernatant, and resuspend the cells in 100ul PBS. To reduce non-specific binding, the Fc receptor (1μg / tube) needs to be blocked beforehand. After incubation at room temperature for 10 minutes, Zombie Violet live / dead dye (1μg / tube) is added, and the cells are incubated at room temperature for 10 minutes, followed by washing. The cells are then resuspended in 100ul PBS buffer containing 1% BSA, and APC / CY7-CD11c, Percp CY5.5-HLA-DR, CD86-PE, and CD80-APC specific antibodies are added. The cells are then stained and incubated at 4°C in the dark for 30 minutes. After staining, cells were washed once with pre-cooled PBS to remove unbound antibodies. Cells were then resuspended in 200 μL of buffer. Forward scatter (FSC) and side scatter (SSC) signals were collected using flow cytometry to set cell population gating. CD11c-positive and Zombie Violet-negative cells were used to identify viable dendritic cells. Flow cytometry gating was used to analyze the percentage of CD86, CD80, and HLA-DR-positive cells in this cell population to quantify changes in maturation marker expression. Fluorescence compensation correction was performed using a single-positive microsphere control. Data analysis was performed using FlowJo software, and the results are as follows: Figure 5 As shown.

[0116] Figure 5 This is a flow cytometry result of Example 2 of this application, showing the phagocytic function of SAA1-stimulated MoDCs, including CD80, CD86, and HLA-DR.

[0117] according to Figure 5It can be seen that in the monocyte-derived dendritic cell (MoDCs) model derived from three healthy subjects, the proportions of CD80, CD86, and HLA-DR positive cells in the SAA1 treatment group were significantly higher than those in the blank control group and the positive control LPS group. The heterogeneity of MoDCs is extremely high. This cross-donor experiment confirms that SAA1 has the ability to stably induce the expression of co-stimulatory molecules (CD80 / CD86) and antigen-presenting molecules (HLA-DR) on the surface of MoDCs across individuals. Its induction efficiency is higher than that of the classic activator LPS under specific concentration (0.5 μg / mL) and specific time (6 hours).

[0118] (4) Detection of DCs inflammation-related genes - RT-qPCR: RNA was extracted from dendritic cells using TRIzol (Invitrogen) and PrimeScript was used. TM RT Master Mix (Takara Bio) was used to convert RNA to cDNA. Real-time quantitative PCR was performed using SYBRPremix Ex Taq™ II (Takara Bio). Relative RNA expression levels were normalized relative to GAPDH mRNA using the ΔΔCt calculation method. Results are shown below. Figure 6 As shown.

[0119] The primers used are as follows:

[0120] GAPDH

[0121] Forward: SEQ ID NO.9: 5'-TCAACGACCACTTTGTCAAGCTCA-3';

[0122] Reverse: SEQ ID NO. 10: 5'-GCTGGTGGTCCAGGGGTCTTACT-3'.

[0123] IL-1β

[0124] Forward: SEQ ID NO.11: 5'-ATGATGGCTTATTACAGTGGCAA-3';

[0125] Reverse: SEQ ID NO.12: 5'-GTCGGAGATTCGTAGCTGGA-3'.

[0126] TNF-α

[0127] Forward: SEQ ID NO.13: 5'-CCTCTCTCTAATCAGCCCTCTG-3';

[0128] Reverse: SEQ ID NO.14: 5'- GAGGACCTGGGAGTAGATGAG- 3'.

[0129] IL-6

[0130] Forward: SEQ ID NO.15: 5'- ACTCACCTCTTCAGAACGAATTG - 3';

[0131] Reverse: SEQ ID NO. 16: 5' - CCATCTTTGGAAGGTTCAGGTTG - 3'.

[0132] Figure 6 This is a graph showing the results of RT-qPCR detection of the expression of SAA1-stimulated MoDCs-related inflammatory factor mRNAs in Example 2 of this application, including IL-1β, IL-6, and TNF-α.

[0133] according to Figure 6 It can be seen that SAA1 can increase the expression of IL-1β and IL-6 genes by nearly 100 times and the expression of TNF-α gene by 20 times in MoDC dendritic cells compared with the control group, and promote the expression of inflammatory factors. This data corresponds functionally with the upregulation results of co-stimulatory molecules (CD80 / CD86 / CD83) detected by flow cytometry, indicating that SAA1 promotes the maturation and activation of MoDCs and polarization of immune response by reshaping the cytokine microenvironment.

[0134] (5) DCs inflammatory factor secretion experiment - CBA multifactor flow cytometry:

[0135] Cell culture supernatant was collected during the 6-hour induction period, and an equal volume of 25 μL was used for flow cytometry multifactor detection using LEGENDplex. TM A mouse cytokine analyzer (Biolegend) was used to measure cytokines in mouse plasma. The LEGENDplex was used. TM Data analysis software (version 8.0) was used to perform data analysis, and the results are as follows: Figure 7 As shown.

[0136] Figure 7 This is a flow cytometry result diagram of the multifactor flow cytometry detection of inflammatory factors secreted in the supernatant of SAA1-stimulated MoDCs cells using a flow microsphere array (CBA) according to Example 2 of this application, including IL-6, TNF-α, IL-1β, IL-12, IL-10, and IL-4.

[0137] according to Figure 7It can be seen that, compared with the control group, the SAA1 group can induce an increase in pro-inflammatory factors such as IL-6, TNF-α, IL-1β, IL12P40, and IL-10 secreted by MoDCs dendritic cells into the supernatant, while simultaneously decreasing anti-inflammatory factors such as IL-4. Notably, the synchronous increase in IL-10 may reflect the initiation of a negative feedback regulatory mechanism. This co-expression of pro-inflammatory / anti-inflammatory factors is common in chronic inflammation, suggesting that SAA1 may be involved in the dynamic balance of inflammatory homeostasis. The release of inflammatory factors not only directly participates in T cell differentiation but also forms a positive feedback regulatory network of cytokines and co-stimulatory molecules, ultimately driving the functional transformation of DCs from immune tolerance to immune activation. This indicates that SAA1 efficiently promotes the functional transformation of dendritic cells from an immune-tolerant state to an immune-activated state.

[0138] (6) Immunoblotting of DCs Inflammatory Factors: To detect changes in the protein level of SAA1-induced inflammatory factors in MoDCs, stimulation of MoDCs with SAA1 for 3 hours resulted in the production of a large amount of TNF-α protein. The method was as follows: Neutrophils were lysed on ice using RIPA buffer (Huaxingbio) in combination with a mixture of protease inhibitors and phosphatase inhibitors (Thermo Fisher Scientific). The protein concentration of the lysate was determined using a BCA protein assay kit (Thermo Fisher Scientific). The RIPA lysis buffer was boiled with loading buffer at 95°C for 10 minutes, followed by electrophoresis, and then transferred to a PVDF membrane (Biorad). The membrane was blocked and then incubated overnight at 4°C with anti-TNF-α (1:1000, abcam) and anti-GAPDH (1:10000, abcam) antibodies. The membrane was washed and incubated for 1 hour with anti-rabbit IgG-HRP (1:5000). The protein bands were visualized using a Tanon-5200 Western blot detection system (Bio-Tanon, Inc.), and the results are shown below. Figure 8 As shown.

[0139] Figure 8 This is a graph showing the results of Western blot analysis of the expression level of the inflammatory factor TNF-α in SAA1-stimulated MoDCs cells in Example 2 of this application.

[0140] according to Figure 8 It can be seen that the control group does not express TNF-α protein, while SAA1 stimulation for three hours can cause a significant increase and presentation of TNF-α protein.

[0141] Example 3: Preparation of dendritic cells derived from human monocytes

[0142] Peripheral blood was collected from healthy volunteers using K2E EDTA anticoagulant tubes. The peripheral blood was diluted with an equal volume of PBS and slowly added to the supernatant of Ficoll-Hypaque separation medium. The mixture was then centrifuged at 800 g for 20 min at room temperature. After centrifugation, the middle white cell layer was aspirated to obtain human peripheral blood mononuclear cells. The obtained cells were washed with PBS, centrifuged at 300 g for 10 min, the supernatant was discarded, and the cells were resuspended in MACS Buffer for subsequent CD14-positive mononuclear cell sorting.

[0143] Peripheral blood mononuclear cells were magnetically sorted using CD14 MicroBeads. The appropriate volume of MACS Buffer and CD14 MicroBeads was added according to the cell number, and the cells were incubated at 4°C in the dark for 15 min. The cells were then washed with MACS Buffer, and the cell suspension was added to a pre-washed magnetic sorting column. After washing the column, it was removed from the magnetic field, and MACS Buffer was added to elute any cells remaining in the column, yielding CD14-positive mononuclear cells. The purity of the obtained CD14-positive mononuclear cells was verified by flow cytometry.

[0144] CD14-positive monocytes obtained through sorting were seeded into six-well plates and cultured in RPMI 1640 complete medium containing 10% FBS and 1% antibiotics. GM-CSF 100 ng / mL and IL-4 20 ng / mL were added to the culture system to induce differentiation. The medium was changed during culture based on the color of the medium and the cell state. After 5-6 days of induction, the cells gradually transitioned from a suspension state to a semi-adherent state, yielding immature human monocyte-derived dendritic cells. After cell collection, the medium was replaced with complete medium without GM-CSF for subsequent activation and drug intervention experiments.

[0145] Example 4: Effects of Celastrol, Triptolide, and Wilforine on rSAA1-induced expression of maturation markers on the surface of human monocyte-derived dendritic cells

[0146] Human monocyte-derived dendritic cells prepared in Example 3 were used to establish four treatment groups: a Vehicle control group, an rSAA1 treatment group, an rSAA1+Celastrol treatment group, an rSAA1+Triptolide treatment group, and an rSAA1+Wilforine treatment group. rSAA1 was recombinant human SAA1, with a final concentration of 0.5 μg / mL, and the stimulation time was 6 h. The final concentrations of Celastrol, Triptolide, and Wilforine were 20 μM, 100 nM, and 100 μM, respectively. Celastrol, Triptolide, or Wilforine were co-treated with rSAA1 in the cell culture system.

[0147] Cells were collected after treatment, and the expression of maturation markers on the surface of dendritic cells was detected by flow cytometry. Briefly, after washing with PBS, cells were blocked with Fc receptor blocking reagent, followed by the addition of fluorescent antibodies related to CD11c, HLA-DR, CD86, and CD83, and incubated at 4°C in the dark. After staining, cells were washed with PBS and resuspended for flow cytometry analysis. The target cell population was obtained through FSC / SSC gating, and the proportions of HLA-DR, CD86, and CD83 positive cells were analyzed within the CD11c-positive human monocyte-derived dendritic cell population. Data were analyzed using FlowJo software, and the results are as follows: Figure 9 and Figure 10 As shown.

[0148] The antibody information used is as follows:

[0149] APC anti-human CD11c, manufacturer: BioLegend, catalog number: 337207, dilution ratio: 1:100; PerCP / Cyanine5.5 anti-human HLA-DR Antibody, manufacturer: BioLegend, catalog number: 307630, dilution ratio: 1:100; PE anti-human CD86, manufacturer: BioLegend, catalog number: 374206, dilution ratio: 1:100; FITC anti-human CD83, manufacturer: BioLegend, catalog number: 305306, dilution ratio: 1:100.

[0150] Figure 9 Figure 4 shows the results of the effects of celastrol, triptolide, and wilforine on rSAA1-induced HLA-DR and CD86 expression in human monocyte-derived dendritic cells in Example 4 of this application. Figure 10This is a diagram showing the effects of celastrol, triptolide, and wilforine on rSAA1-induced CD83 expression in human monocyte-derived dendritic cells, as described in Example 4 of this application.

[0151] according to Figure 9 It can be seen that rSAA1 treatment can induce an increase in the proportion of HLA-DR and CD86 positive cells in human monocyte-derived dendritic cells; compared with rSAA1 treatment alone, co-treatment with Celastrol and Triptolide reduced the proportion of HLA-DR and CD86 positive cells, suggesting that both can inhibit rSAA1-induced co-stimulation and antigen-presenting-related molecule expression in human monocyte-derived dendritic cells. Wilforine's inhibitory effect was weaker than that of Celastrol and Triptolide, or it did not show the same degree of inhibitory effect under the same conditions.

[0152] according to Figure 10 It can be seen that rSAA1 treatment can induce an increase in the proportion of CD83-positive cells in human monocyte-derived dendritic cells; compared with rSAA1 treatment alone, co-treatment with Celastrol and Triptolide reduced the proportion of CD83-positive cells, suggesting that both can inhibit rSAA1-induced maturation and activation of human monocyte-derived dendritic cells. Wilforine had a weaker or less obvious inhibitory effect.

[0153] Example 5: Effects of Celastrol, Triptolide, and Wilforine on rSAA1-induced secretion of inflammatory factors in human monocyte-derived dendritic cells.

[0154] Human monocyte-derived dendritic cells prepared in Example 3 were treated according to the grouping in Example 4. The final concentration of rSAA1 was 0.5 μg / mL, and the stimulation time was 6 h. The final concentrations of Celastrol, Triptolide, and Wilforine were 20 μM, 100 nM, and 100 μM, respectively. Celastrol, Triptolide, or Wilforine were co-treated with rSAA1 and added to the cell culture system.

[0155] After processing, cell culture supernatant was collected, and the levels of inflammatory factors in the supernatant were detected using the CBA method. The detected indicators included IL-6, TNF-α, and IL-1β. CBA assays were performed according to the kit instructions, and the data were processed using appropriate analysis software. Results are shown below. Figure 11 As shown.

[0156] Figure 11The figure shows the effect of Celastrol, Triptolide, and Wilforine on the secretion of inflammatory factors by rSAA1 induced by human monocyte-derived dendritic cells in Example 5 of this application.

[0157] like Figure 11 As shown, rSAA1 treatment promoted the secretion of IL-6, TNF-α, and IL-1β by human monocyte-derived dendritic cells; compared with rSAA1 treatment alone, co-treatment with Celastrol and Triptolide reduced the secretion levels of these inflammatory factors. Wilforine showed weak or no inhibitory effect. The experimental samples were obtained from 3 healthy subjects, and the statistical analysis was performed using paired one-way ANOVA.

[0158] The results indicate that Celastrol and Triptolide can not only reduce the expression of rSAA1-induced maturation markers on the surface of human monocyte-derived dendritic cells, but also reduce the secretion of rSAA1-induced inflammatory factors.

[0159] Example 6: Effects of Celastrol, Triptolide, and Wilforine on rSAA1-induced expression of inflammatory cytokines mRNA in human monocyte-derived dendritic cells.

[0160] Human monocyte-derived dendritic cells prepared in Example 3 were treated according to the grouping in Example 4. The final concentration of rSAA1 was 0.5 μg / mL, and the stimulation time was 6 h. The final concentrations of Celastrol, Triptolide, and Wilforine were 20 μM, 100 nM, and 100 μM, respectively. Celastrol, Triptolide, or Wilforine were co-treated with rSAA1 and added to the cell culture system.

[0161] Cells were collected after treatment, and total RNA was extracted using TRIzol and reverse transcribed into cDNA using PrimeScript RT MasterMix. Real-time quantitative PCR was performed using the SYBR Green Cell PCR system. Relative expression levels were calculated using the 2-ΔΔCt method, with GAPDH as an internal reference gene. Genes detected included IL6, TNF, and IL1β. Results are shown below. Figure 12 As shown.

[0162] The human qPCR primers used were the same as those in Example 2, SEQ ID NO.9 to SEQ ID NO.16.

[0163] Figure 12The figure shows the effect of Celastrol, Triptolide, and Wilforine on the mRNA expression of IL6, TNF, and IL1B induced by rSAA1 in human monocyte-derived dendritic cells, as described in Example 6 of this application.

[0164] according to Figure 12 It was observed that rSAA1 treatment upregulated the mRNA expression of IL6, TNF, and IL1B in human monocyte-derived dendritic cells; compared with rSAA1 treatment alone, co-treatment with Celastrol and Triptolide reduced the relative mRNA expression levels of IL6, TNF, and IL1B. Wilforine showed weak or insignificant inhibitory effects. The experimental samples were derived from six healthy subjects, and statistical analysis was performed using paired one-way ANOVA.

[0165] The results indicate that Celastrol and Triptolide can suppress rSAA1-induced inflammatory responses in human monocyte-derived dendritic cells at the transcriptional level.

[0166] Example 7: Effects of Celastrol, Triptolide, and Wilforine on the temporal gradient of rSAA1-induced transcription of inflammatory factors in mouse bone marrow-derived dendritic cells

[0167] This embodiment was used to evaluate the effects of Celastrol, Triptolide, and Wilforine on rSAA1-induced transcription of inflammatory factors in mouse bone marrow-derived dendritic cells.

[0168] Eight- to ten-week-old male C57BL / 6 mice were euthanized using CO2, and the femur and tibia were isolated. Under aseptic conditions, the bone marrow cavity was washed with PBS to obtain a bone marrow cell suspension. After centrifugation, the cells were lysed with erythrocytes, washed with PBS, and filtered through a filter to obtain a single-cell suspension.

[0169] The magnetic bead sorting step reduced the influence of neutrophils or their precursor cells on the subsequent dendritic cell induction system. The treated bone marrow cells were cultured in RPMI 1640 complete medium supplemented with GM-CSF 20 ng / mL and IL-4 10 ng / mL to induce differentiation. The cell seeding density was 1 × 10⁻⁶ cells / mL. 6 Cells / mL, 3 mL per well. Cells were cultured at 37°C and 5% CO2, with medium changed on days 3 and 5. Immature mouse bone marrow-derived dendritic cells were obtained after 5–7 days of culture.

[0170] Dendritic cells derived from the bone marrow of immature mice were collected, and after adjusting the cell concentration, they were seeded into 12-well plates. Vehicle control group, rSAA1 treatment group, rSAA1+Celastrol treatment group, rSAA1+Triptolide treatment group, and rSAA1+Wilforine treatment group were set up.

[0171] rSAA1 was derived from recombinant mouse SAA1 protein at a final concentration of 0.5 μg / mL. Celastrol was added at a final concentration of 20 μM, Triptolide at 100 nM, and Wilforine at 100 μM. Celastrol, Triptolide, or Wilforine were co-treated with rSAA1 and added to the cell culture system. Cells were collected at 0, 3, 5, and 7 h.

[0172] Total RNA was extracted using TRIzol and subjected to reverse transcription and real-time quantitative PCR. Relative expression levels were calculated using the 2-ΔΔCt method, with β-Actin used as an internal reference gene. Genes detected included Il1b, Il6, Tnf, and Il12. Results are shown below. Figure 13 As shown.

[0173] The mouse qPCR primers used were the same as those in Example 1 (SEQ ID NO.1 to SEQ ID NO.8).

[0174] Figure 13 This figure shows the temporal gradient effects of Celastrol, Triptolide, and Wilforine on rSAA1-induced transcription of inflammatory factors in mouse bone marrow-derived dendritic cells, as described in Example 7 of this application. This experiment was a small-sample temporal gradient validation experiment (n=2) to demonstrate the trend of changes in transcriptional changes of different active ingredients of Tripterygium wilfordii on inflammatory factors in mouse-derived dendritic cells.

[0175] according to Figure 13 It can be seen that the inhibitory effect of Celastrol and Triptolide on rSAA1-induced inflammatory transcriptional response in dendritic cells can also be observed in mouse-derived dendritic cells. In a small-sample time gradient validation experiment, the expression of Il1b, Il6, Tnf, and Il12 mRNA induced by rSAA1 in mouse bone marrow-derived dendritic cells changed over time. Compared with rSAA1 treatment alone, the Celastrol and Triptolide co-treatment group showed a decreasing trend in the transcriptional level of inflammatory factors at multiple time points.

[0176] In summary, Celastrol and Triptolide can inhibit rSAA1-induced expression of maturation markers, inflammatory cytokine secretion, and inflammatory cytokine mRNA expression on the surface of human monocyte-derived dendritic cells, and show a trend of inhibiting inflammatory cytokine transcription in mouse bone marrow-derived dendritic cell time gradient experiments. These results suggest that Celastrol and Triptolide can be preferred active ingredients of Tripterygium wilfordii for inhibiting SAA1-induced abnormal activation of dendritic cells.

[0177] The specific embodiments described above further illustrate the purpose, technical solution, and beneficial effects of this application. It should be understood that the above descriptions are merely specific embodiments of this application and are not intended to limit this application. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. An application of SAA1 protein in inducing the maturation and activation of immature dendritic cells, comprising: Contact the SAA1 protein with immature dendritic cells; The induction concentration of the SAA1 protein was 0.1 ng / mL to 10 μg / mL, and the induction time was 6 to 8 hours.

2. The application according to claim 1, wherein, The immature dendritic cells are derived from human mononuclear cells or mouse bone marrow.

3. The application according to claim 1, wherein, The induction concentration of the SAA1 protein is from 0.1 μg / mL to 5 μg / mL, preferably 0.5 μg / mL.

4. The application according to claim 2, wherein, The immature dendritic cells derived from human mononuclear cells were obtained and matured / activated using the following methods: Mononuclear cells were isolated from the peripheral blood of the subjects and CD14-positive mononuclear cells were obtained by CD14 magnetic bead sorting. The CD14-positive monocytes were induced to differentiate into immature dendritic cells in a culture medium containing granulocyte-macrophage colony-stimulating factor and interleukin-4. The immature dendritic cells were contacted with SAA1 protein to activate and mature them, thus obtaining mature dendritic cells. The concentration of the granulocyte-macrophage colony-stimulating factor is 80 ng / mL to 120 ng / mL, preferably 100 ng / mL; The concentration of interleukin-4 is from 15 ng / mL to 25 ng / mL, preferably 20 ng / mL.

5. The application according to claim 2, wherein, The immature dendritic cells derived from mouse bone marrow were obtained and matured / activated using the following method: Bone marrow cells were isolated from mouse bone marrow, and neutrophils were removed by negative magnetic bead sorting to obtain dendritic cell precursors. The dendritic cell precursors were induced to differentiate into immature dendritic cells in a culture medium containing granulocyte-macrophage colony-stimulating factor and interleukin-4. The immature dendritic cells were contacted with SAA1 protein to activate and mature them, thus obtaining mature dendritic cells. The concentration of the granulocyte-macrophage colony-stimulating factor is 15 ng / mL to 25 ng / mL, preferably 20 ng / mL. The concentration of interleukin-4 is from 5 ng / mL to 15 ng / mL, preferably 10 ng / mL.

6. The application of a Tripterygium wilfordii active ingredient in the preparation of a drug that inhibits SAA1-induced dendritic cell activation; The active ingredients of Tripterygium wilfordii are triptolide and / or triptolide A.

7. The application according to claim 6, wherein, The active ingredients of Tripterygium wilfordii include its pharmaceutically acceptable salts, derivatives, analogs, prodrugs, crystal forms, hydrates, solvates, or pharmaceutical compositions.

8. The application according to claim 6, wherein, Dendritic cell activation includes increased expression of dendritic cell maturation markers, increased expression of antigen-presenting related molecules, increased expression of co-stimulatory molecules, increased expression of inflammatory factors, or increased secretion of inflammatory factors. The maturity markers, antigen-presenting related molecules, or co-stimulatory molecules include one or more of HLA-DR, CD86, CD83, CD80, MHCII, and CD40; The inflammatory factors include one or more of IL-6, TNF-α, IL-1β, and IL-12.

9. The application according to claim 6, wherein, The diseases associated with high levels of SAA1 include: SAA1-related inflammatory diseases, SAA1-involved immune inflammatory diseases, diseases related to abnormal dendritic cell activation, autoimmune diseases, chronic inflammatory diseases, inflammation-related fibrotic diseases, tissue damage-related inflammatory diseases, post-infectious inflammatory responses, or aseptic inflammatory responses.

10. The application according to claim 9, wherein, The diseases mentioned include joint inflammation-related diseases, lung inflammation-related diseases, pulmonary fibrosis-related diseases, intestinal inflammation-related diseases, liver inflammation-related diseases, vascular inflammation-related diseases, post-infectious inflammatory syndromes, or autoimmune-related inflammatory diseases.